VIEWPOINT

Interferon-stimulated gene products as regulators of central carbon metabolism

Kourosh H. Ebrahimi[1] (iD), Javier Gilbert-Jaramillo[2,3] (iD), William S. James[2] (iD) and James S.O. McCullagh[1] (iD)

1 Chemistry Research Laboratory, Department of Chemistry, University of Oxford, UK
2 Sir William Dunn School of Pathology, University of Oxford, UK
3 Department of Physiology, Anatomy and Genetics, University of Oxford, UK

In response to viral infections, the innate immune system rapidly activates expression of several interferon-stimulated genes (ISGs), whose protein and metabolic products are believed to directly interfere with the viral life cycle. Here, we argue that biochemical reactions performed by two specific protein products of ISGs modulate central carbon metabolism to support a broad-spectrum antiviral response. We demonstrate that the metabolites generated by metalloenzymes nitric oxide synthase and the radical S-adenosylmethionine (SAM) enzyme RSAD2 inhibit the activity of the housekeeping and glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH). We discuss that this inhibition is likely to stimulate a range of metabolic and signalling processes to support a broad-spectrum immune response. Based on these analyses, we propose that inhibiting GAPDH in individuals with deteriorated cellular innate immune response like elderly might help in treating viral diseases such as COVID-19.

Introduction

Central carbon metabolism converts sugars into a range of metabolic precursors that are used to generate biomass and energy required for the cellular function [1] (Fig. 1A). Consequently, remodelling of central carbon metabolism occurs in many human diseases such as cancer [2] and is at the forefront of the host–pathogen interactions. Pathogens like bacteria or viruses are dependent on host cellular metabolites and proteins to support their reproduction. To fight viral infections, all cells are equipped with a nonspecific response consisting of the expression of several proteins and enzymes, induced by different types of interferons, and thus, are referred to as interferon-stimulated gene (ISG) products. Most previous studies have led to the conclusion that the protein products of these genes directly act on the viral life cycles to restrict their replication [3,4]. On the contrary, we propose a new model based on available data in the literature and an analogy from a system engineering perspective (Fig. 1B): A cell can be considered as a factory and central carbon metabolism as the main process for converting a raw material to products and energy for the factory to function (Fig. 1B). When an infectious agent enters the factory, it will highjack the main process and use the products for its reproduction. Under this circumstance, the first response of the control room would be to use some of the available products in a second reaction (analogous to the function of ISGs) to directly

Abbreviations

1,3-BPG, 1,3-biphosphoglycerate; COVID-19, coronavirus disease 2019; cADPR, cyclic ADP-ribose; ddhCTP, 3'-deoxy-3',4'-didehydro analogue; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; G3P, glyceraldehyde 3-phosphate; hiPSCs, human induced pluripotent stem cells; ISG, interferon-stimulated gene; NFAT, nuclear factor of activated T cells; NOS, nitric oxide synthase; RSAD2, radical S-adenosylmethionine domain-containing protein 2; RdRps, RNA-dependent RNA polymerases; SAM, S-adenosylmethionine.

Fig. 1. Central carbon metabolism and viral infection. (a) Central carbon metabolism (glycolysis, pentose phosphate pathway and TCA cycle) converts sugars to the building blocks of DNA and RNA, proteins and lipids. Additionally, it generates energy in the form of ATP and redox cofactors NAD^+/NADH and $NADP^+$/NADPH. Abbreviations: LDs, lipid droplets; G6P, glucose 6-phosphate; F6P, fructose 6-phosphate; FBP, fructose 1,6-biphosphate; G3P, glyceraldehyde 3-phosphate; DHAP, dihydroxyacetone phosphate; 1,3-BPG, 1,3-biphosphoglycerate; 3PG, 3-phosphoglycerate; 2PG, 2-phosphoglycerate; PEP, phosphoenolpyruvate; 2-OG, 2-oxoglutarate. (b) A systems engineering analogy describing function of the protein products of ISGs as (1) direct effectors of viral replication and (2) in the remodelling of central carbon metabolism to support broad-spectrum immune response. The cell is like a factory and central carbon metabolism is the process 1. If an infectious agent enters the factory, the first response of the control room would be to use some of the available products and energy (process 2) to either directly inhibit viral replication (path 1) or to inhibit the production process (path 2). The outcomes of path 2 will be (i) reduction in formation of products and energy to limit access of pathogen to these resources and (ii) support of process 3, which restricts replication of the infectious agent.

block viral replication and to inhibit the main process. This would limit the nutrients for the reproduction of the infectious agent, while redirecting the materials and energy to a third process that can eliminate the invading agent. Accordingly, we suggest that the metabolites generated by some ISG proteins contribute to the remodelling of the central carbon metabolism in support of a broad-spectrum antiviral immune response. We discuss emerging evidence that supports this model. We show how the early metabolites generated by the biochemical reactions of two ISG metalloenzymes, namely nitric oxide synthase (NOS) and the radical-SAM enzyme RSAD2, inhibit the glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and how this inhibition is likely to support a broad-spectrum antiviral immune response.

Mechanisms adopted by cells to inhibit GAPDH

GAPDH is a housekeeping protein catalysing a critical step in glycolysis, with additional functions in DNA repair [5], cytoskeletal dynamics and vesicular trafficking between cellular compartments [6] and redox signalling and apoptosis [7]. As a glycolytic enzyme, it catalyses the NAD^+-dependent transformation of glyceraldehyde 3-phosphate (G3P or GAP) to 1,3-biphosphoglycerate (1,3-BPG) (Fig. 1A). Metabolomic analysis together with computational studies have revealed that flux through GAPDH is a rate-limiting step in glycolysis [8]. Here, we discuss mechanisms adopted by the cellular innate immune response to inhibit NAD^+-dependent conversion of G3P by

GAPDH, focussing on those associated with ISG products specifically rather than other mechanisms such as malonylation [9].

Inhibition of GAPDH by ddhCTP ribonucleotide analogue generated by RSAD2 (viperin)

Radical S-adenosylmethionine (SAM) domain-containing protein 2 (RSAD2) also known as viperin is a member of the radical-SAM superfamily of enzymes [10]. The RSAD2 gene is an interferon-stimulated gene (ISG) whose expression is induced by type-I, type-II and type-III interferons, directly by viruses and by LPS [11–18]. It is known that expression of RSAD2 restricts replication of a wide range of RNA and DNA viruses in different cells [19,20] and this effect is proposed to result from an altered metabolic state [21]. Biochemical and cell biological studies revealed that RSAD2 can catalyse the transformation of CTP to its 3'-deoxy-3',4'-didehydro analogue (ddhCTP) [22]. Isotope labelling experiments [22], structural analysis [23] and biochemical studies [24] have also shed light on the enzymatic mechanism. Biochemical experiments showed that ddhCTP may act as a chain terminator of viral RNA-dependent RNA polymerases (RdRps) (IC_{50} > 20,000 μM) [22]. It should be noted that the reported IC_{50} values of ddhCTP as a chain terminator of viral RdRps were not corrected for the observed background effect of CTP on biochemical assays used to measure chain-termination activity [25]. Nevertheless, if ddhCTP acts as a chain terminator of viral RdRps, the question that arises is why does then the cellular activity of RSAD2 affects many processes like glucose homeostasis [26] and expression of immune-related genes [27]? To answer this fundamental question, metabolomic experiments using HEK293T cells and macrophages derived from human induced pluripotent stem cells (hiPSCs) were used. It was discovered that cellular activity of RSAD2 diminishes activity of NAD^+-dependent enzymes including that of GAPDH inside cells (Fig. 2) increasing intracellular levels of G3P and metabolites of pentose phosphate pathway [25,28]. Subsequent biochemical studies confirmed that ddhCTP inhibits activity of GAPDH in a test tube with an IC50 value of 55.8 ± 0.2 μM [25]. This value is bout 400-fold less than the reported IC_{50} value of ddhCTP as chain terminator and is less than the reported cellular concentration of ddhCTP (100–300 μM) [22]. These data suggest that under physiological conditions ddhCTP is more efficient in inhibiting GAPDH than acting as a chain terminator of RdRps.

S-nitrosylation

Nitric oxide (NO) has emerged as a key player in innate immune response to bacterial and viral pathogens [29,30]. It is synthesized from L-arginine by the catalytic function of the metalloenzyme nitric oxide synthase (NOS). In humans at least three isoforms of NOS have been reported (NOS-I, NOS-II and NOS-III) [31,32]. These metalloenzymes have binding sites for NADPH, FMN, FAD and calmodulin (CaM). The active site of all three isoforms has a haem cofactor and catalyses conversion of L-arginine to NO and L-citrulline in two steps [33]. Several reports have shown that NO induces S-nitrosylation of GPADH, which inhibits its activity (Fig. 2) [34–38]. It is suggested that S-nitrosylation of the active site thiol leads to nonenzymatic ADP-ribosylation, which inactivates the protein [37].

Inhibition of GAPDH and a broad-spectrum antiviral response

Inhibition of GAPDH by ddhCTP or S-nitrosylation will likely result in an increase in the cellular availability of NAD^+. This will support protein ADP-ribosylation and biosynthesis of cyclic ADP-ribose (cADPR) [39,40] (Fig. 3), both of which require NAD^+ as a substrate. Consistently, it is shown that S-nitrosylation of GAPDH and inhibition of its activity increases endogenous protein ADP-ribosylation [34]. ADP-ribosylation is shown to increase proteasomal activity [41,42]. cADPR on the other hand, is a second messenger metabolite involved in modulation of Ca^{2+} signalling and homeostasis [43–45] (Fig. 3A). cADPR binds to ryanodine receptor (RyRs), which is expressed in many cell types including macrophages and T cells [46], and initiates the release of Ca^{2+} from the intracellular store (Fig. 3) [47–49]. Aligned with these observations, it has been shown that the cellular level of NAD^+ controls Ca^{2+} store and release [50].

Inhibition of GAPDH can also increase the cellular availability of G3P. Consistently, macrophages expressing RSAD2, which can produce ddhCTP, show a higher intracellular level of G3P as compared to RSAD2-KO macrophages [25]. Increase in the cellular availability of G3P supports biosynthesis of triacylglycerols (TAGs) and phosphatidylcholine (PC), which are the building blocks of lipid droplets (LDs) [51,52]. G3P is converted to dihydroxyacetone phosphate (DHAP) by the catalytic activity of triosephosphate isomerase (Fig. 3). Subsequently, DHAP is converted by the NADH-dependent activity of glycerol-3-phosphate dehydrogenase (GPDH) to glycerol-3-phosphate

Fig. 2. The early response of the cellular innate immune system inhibits NAD^+-dependent activity of GAPDH. In response to interferons, viruses or bacteria, the cells express metalloenzymes RSAD2 (viperin) and/or nitric oxide synthase (NOS). RSAD2 uses S-adenosylmethionine (SAM) to catalyse transformation of CTP to ddhCTP, which inhibit activity of GAPDH. 5′-deoxyadenosine (5′-dA) is formed as a by-product. On the other hand, NOS generates NO, which induces S-nitrosylation of GAPDH and inhibits its activity.

(Fig. 3). Next, in a series of enzymatic reactions [52], which have been studied since early 1950s and are localized at the cytosolic face of the endoplasmic reticulum (ER), glycerol-3-phosphate and fatty acyl-CoA are combined to generate TAGs and PC. Consistently, using ^{13}C-labelling experiments it was found that upon formation of classically activated macrophages (M1 macrophages), in which expression of RSAD2 is highly induced [53], formation of LD increases and the carbon for the synthesis of LDs originates from G3P [54].

Stimulation of proteasome activity by ADP-ribosylation, cADPR-dependent stimulation of Ca^{2+} release from the cellular stores, and an increase in biosynthesis of TAGs and PC, is likely to support a systemic immune response in cells in at least four ways (Fig. 4):

a. Eicosanoids storm: Eicosanoids have a wide range of functions in inflammation and immune response to pathogens. Overall, available data suggest that eicosanoids can have both pro-inflammatory and anti-inflammatory activities depending on context and thus, may contribute to a balanced immune response [55]. It has been established that LDs are not just fat-storing organelles and that they are important mediators of the innate immune response to pathogens [56]. LDs are shown to be a site for biosynthesis

of eicosanoids [57]. Formation of eicosanoids occurs via a complex and highly regulated process [57] starting with liberation of arachidonic acid (AA) from phospholipids by Ca^{2+}-dependent phospholipases (PL)A_2 [58,59]. In different cells including innate immune cells like macrophages, the LDs are rich in AA [60–64]. Characterization of lipid droplets in different cells has revealed that enzymes involved in catalytic conversion of AA to eicosanoid like PGE_2, namely cyclooxygenase 1 and 2 (COX1 and COX2), are localized to the LDs [65]. These data strongly suggest that LDs are at least partially involved in synthesis of inflammatory eicosanoids from AA and their downstream signalling pathways. Inhibition of GAPDH is likely to support LDs-mediated eicosanoids biosynthesis in at least two ways: (i) increase in the cellular availability of G3P for biosynthesis of TAGs and PC and formation of LDs (Fig. 4A) and (ii) increase in the cellular availability of NAD^+ and induction of cADPR-dependent release of Ca^{2+} from cellular stores to support activity of the Ca^{2+}-dependent phospholipases PLA_2 and liberation of AA (Fig. 4A).

b. Antigen cross-presentation via major histocompatibility class I: This process requires proteasomal

Fig. 3. Inhibition of GAPDH increases the intracellular availability (blue arrow) of glyceraldehyde 3-phosphate (G3P) and NAD$^+$. An increase in the availability of G3P will support biosynthesis of TAGs and PC, which are the building blocks of lipid droplets (LDs). Increase in the availability of NAD$^+$ will support synthesis of cADPR and ADP-ribosylation. cADPR activates RyR receptor and induces release of Ca^{2+} from the cellular stores. ADP-ribosylation can increase proteasomal activity and formation of peptide antigens.

activity and LDs. An increase in proteasomal activity increases the rate of formation of peptide antigens for cross-presentation via major histocompatibility class I (MHC-I) [66–68]. In many cell types including macrophages and DCs, a major path of antigen cross-presentation involves transfer of peptide antigen into the endoplasmic reticulum (ER) lumen by the ATP-dependent function of the TAP system (Fig. 4A) [69,70]. In the ER lumen, peptide antigens bind to MHC-1 and the complex is transported to the cell surface for presentation to CD8$^+$ T cells. A mechanism of transportation to the cell surface is through LDs [56]. In dendritic cells (DCs), the immune-related GTPs protein, namely Irgm3, localizes to the LDs [71]. When the gene expressing Irgm3 or adipose differentiation-related protein (ADRP, also known as ADFP), which regulates LD biogenesis and dynamics [72,73], was inactivated, formation of LDs was impaired and cross-presentation of antigen to CD8$^+$ T cells was abrogated [71]. Additionally, saponin-based adjuvants (SBAs), which are used in cancer vaccines, induce formation of LDs in CD11b$^+$ DCs and this increase causes a saponin-dependent increase in antigen cross-presentation and T-cell activation [74]. Therefore, a concomitant increase in the cellular

availability of G3P and NAD$^+$ due to inhibition of GAPDH will ensure formation of LDs as carriers of the MHC-I/antigen complex, and increase proteasomal activity via an ADP-ribosylation pathway to provide the peptide antigens (Fig. 4A). Consistent with this mechanism, the cellular activity of RSAD2 (viperin), which generates the ddhCTP metabolite and inhibits GAPDH, stimulates degradation of Zika virus and tick-borne encephalitis virus nonstructural protein NS3 via a proteasome-dependent manner [75].

c. NFAT- and NF-κB-mediated immune regulation. In innate immune cells like macrophages or T cells release of Ca^{2+} activates a range of immune defence mechanisms (Fig. 3B). Ca^{2+} binds to calmodulin (CaM) and the complex activates the phosphatase calcineurin (CaN) [76,77]. In turn, CaN dephosphorylates and activates nuclear factor of activated T cells (NFAT) [78]. Additionally, CaN plays a role in LPS-induced nuclear factor-κB (NF-κB) activation in macrophages [79–81]. NFAT- and NF-κB regulate expression of several genes involved in immune cell response and function including IL-10, IL-6, IL-8, IFN-1, IFN-2, TNF-α and multiple TLR-inducible genes including iNOS [82–90]. Thus, inhibition of GAPDH by ddhCTP or NO, and the likely

increase in the cellular availability of NAD$^+$, will modulate NFAT- or NF-κB-dependent expression of inflammatory genes. In summary, inhibition of GAPDH and an increase in the cellular level of NAD$^+$ are likely to induce stimulation of cADPR and release of Ca^{2+}. This will modulate activity of NFAT- and NF-κB for a balanced and effective antiviral immune response. There is growing evidence in support of this mechanism. Firstly, when RSAD2 (viperin) gene was knocked out, thereby abrogating the inhibition of GAPDH by ddhCTP, the mRNA level of genes whose expression is regulated by NFAT or NF-κB including iNOS and TNF-α was affected in macrophages [91]. Secondly, NFAT and NF-κB regulate Th2 response [92] and cellular activity of RSAD2 modulates activity of NF-κB and AP1, which interact with NFAT, for optimal Th2 response [93]. Finally, overexpression of viperin upregulates expression of a wide range of immune-related genes including IL-8, IFN-1 and IFN-2 [27], whose expression is regulated by NFAT.

d. Nitric oxide and immune response. In many cells, nitric oxide (NO) is an important product of the innate immune response and has broad-spectrum antiviral and antibacterial activity [94–97]. It can contribute to viral restriction via different mechanisms. NO causes S-nitrosylation of different viral proteins, abolishes their activity and reduces viral replication [98] (Fig. 4B). Viral components, including proteases [99–102], RNA-dependent RNA polymerases (RdRps) [103], and transcriptase [104], are known to be inhibited by NO-mediated S-nitrosylation. Replication of a number of viruses is restricted by NO including herpes simplex virus type 1 [105], Japanese encephalitis virus [106], coxsackievirus [101], dengue virus type 2 (DNGV-2) [103], influenza virus [107] and HIV-1 [102,104]. Additionally, NO can modulate mitochondrial metabolism to induce formation of inflammatory macrophages [108]. Therefore, inhibition of GAPDH and an increase in the cellular availability of NAD$^+$, which will induce cADPR-dependent Ca^{2+} release, will induce activity of iNOS via CaM binding (Fig. 4B). The resulting NO can support a broad-spectrum antiviral response via S-nitrosylation of viral protein or by further modulating the metabolism in immune cells like macrophages.

Concluding remarks

In summary, we demonstrate that the glycolytic and housekeeping enzyme GAPDH is inhibited or modified by the metabolites, namely ddhCTP and NO, produced by two ISG protein products, RSAD2 and nitric oxide synthase, respectively. Inhibition of the NAD$^+$-dependent conversion of G3P by GAPDH supports several downstream metabolic and signalling pathways, specifically biosynthesis of TAGs and PC, which are precursors of LDs, protein ADP-ribosylation and synthesis of cADPR. Together, these metabolites stimulate a balanced immune response via inflammatory eicosanoids, antigen cross-presentation, activation of NFAT and NF-κB and stimulation of formation of NO. This immunometabolic regulation of central carbon metabolism to stimulate a broad-spectrum immune response provides an explanation for the wide range of effects observed due to expression of RSAD2 (viperin) in many cell types: these include the broad-spectrum antiviral response [19], optimal Th2 cytokine production [93], which requires NFAT function [109], modulation of cellular lipid metabolism during human cytomegalovirus and influenza virus infections [110,111], induction of type-1 interferon production in plasmacytoid dendritic cells via a Toll-like receptor-mediated mechanism [112], interference with glucose homeostasis [26] and regulation of macrophage polarization [91].

Our analyses suggest that inhibition of GAPDH by the cellular innate immune response primes a broad-spectrum immune response to viral infection. This is in opposed to recent reports [113,114] suggesting that inhibition of GAPDH reduces immune response and thus, is a potential therapeutic approach for treating inflammatory diseases. These studies are based on use of small molecules such as the drug dimethyl fumarate (DMF) [113], which is used to treat autoimmune diseases, or 4-octyl itaconate [114]. These molecules were suggested to directly modify Cys150 or Cys22, respectively, in GAPDH, and inhibit its activity. This inhibition was linked to a reduction in synthesis of inflammatory cytokines such as TNF-α in T cells and macrophages with the assumption that no other protein in the cell was modified [113,114]. In contrast to this assumption, analysis of global proteome in T cells reveals more than 2400 cysteine residues that could potentially be modified by DMF [115]. It was shown that two cysteine residues in protein kinase Cθ are target of modification by DMF and these modifications interfere with T-cell activation [115].

Because the cellular innate immune response adopts mechanism that leads to inhibition of GAPDH, which as we discussed is likely to induce a broad-spectrum immune response, we propose that in individuals with weakened cellular innate immune system inhibition of GAPDH might be a therapeutic approach to help prime the innate immune response via at least four

Fig. 4. Inhibition of GAPDH and increase in the cellular availability of G3P and NAD$^+$ support a broad-spectrum immune response via at least four mechanisms. (a) Increase in the cellular availability of G3P and NAD$^+$ supports eicosanoid synthesis and antigen cross-presentation via MHC-I. (b) Increase in the cellular availability of NAD$^+$ will induce release of Ca^{2+} from the cellular stores and CaM-dependent activation of NFAT and NF-κB. On the other hand, CaM induces synthesis of NO by iNOS, which promotes S-nitrosylation of viral proteins to restrict viral replication in immune cells like macrophages or modulates TCA cycle to induce formation of inflammatory macrophages.

mechanisms: (i) supporting formation of eicosanoids, (ii) assisting antigen cross-presentation via MHC-I, (iii) mediating immune response via NFAT and NF-κB and (iv) stimulating synthesis of NO. Hence, we speculate that inhibition of GAPDH might help in the treatment of infection with viruses such as SARS-CoV-2. Future works should test the validity of this proposal.

Acknowledgements

Conflict of interest

The authors declare no conflict of interest.

Author contributions

KHE conceived the study and wrote the manuscript with contribution from all the authors.

References

1 Noor E, Eden E, Milo R & Alon U (2010) Central carbon metabolism as a minimal biochemical walk between precursors for biomass and energy. *Mol Cell* **39**, 809–820.

2 Warburg O (1956) On the origin of cancer cells. *Science (80-)* **123**, 309–314.

3 Schoggins JW & Rice CM (2011) Available online at www.sciencedirect.comInterferon-stimulated genes and their antiviral effector functions. *Curr Opin Virol* **1**, 519–525.

4 Schneider WJ, Chevillotte MD & Rice CM (2014) Interferon-stimulated genes: a complex web of host defenses. *Annu Rev Immunol* **32**, 513–545.

5 Meyer-Siegler K, Mauro DJ, Seal G, Wurzer J, DeRiel JK & Sirover MA (1991) A human nuclear uracil DNA glycosylase is the 37-kDa subunit of glyceraldehyde-3-phosphate dehydrogenase. *Proc Natl Acad Sci* **88**, 8460–8464.

6 Zala D, Hinchelmann MV, Yu H, da Gunha MML, Liot G, Cordelieres FP, Marco S & Saudou F (2013) Vesicular glycolysis provides on-board energy for fast axonal transport. *Cell* **152**, 479–491.

7 Hara MR, Agrawal N, Kim SF, Cascio MB, Fujimuro M, Ozeki Y, Takahashi M, Cheah JH, Tankou SK, Hester LD et al, (2005) S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding. *Nat Cell Biol* **7**, 665–674.

8 Shestov AA, Liu X, Ser Z, Cluntun AA, Hung YP, Huang L, Kim D, Le A, Yellen G, Albeck JG & et al, (2014) Quantitative determinants of aerobic glycolysis identify flux through the enzyme GAPDH as a limiting step. *Elife* **3**, e03342.

9 Galvan-Pena S, Carroll RG, Newman C, Hinchy EC, Palsson-McDermott E, Robinson EK, Covarrubias S, Nadin A, James AM, Haneklaus M et al, (2019) Malonylation of GAPDH is an inflammatory signal in macrophages. *Nat Commun* **10**, 338.

10 Duschene KS & Broderick JB (2010) The antiviral protein viperin is a radical SAM enzyme. *FEBS Lett* **584**, 1263–1267.

11 Chin K-C & Cresswell P (2001) Viperin (cig5), an IFN-inducible antiviral protein directly induced by human cytomegalovirus. *Proc Natl Acad Sci USA* **98**, 15125–15130.

12 Severa M, Coccia EM & Fitzgerald KA (2006) Toll-like receptor-dependent and -independent viperin gene expression and counter-regulation by PRDI-binding factor-1/BLIMP1. *J Biol Chem* **281**, 26188–26195.

13 Mikulecky P, Andreeva E, Amara P, Weissenhorn W, Nicolet Y & Macheboeuf P (2018) Human viperin catalyzes the modification of GPP and FPP potentially affecting cholesterol synthesis. *FEBS Lett* **592**, 199–208.

14 Seo J-Y, Yaneva R & Cresswell P (2011) Viperin: a multifunctional, interferon-inducible protein that regulates virus replication. *Cell Host Microbe* **10**, 534–539.

15 Helbig KJ & Beard MR (2014) The role of viperin in the innate antiviral response. *J Mol Biol* **426**, 1210–1219.

16 Seo J-Y, Yaneva R, Hinson ER & Cresswell P (2011) Human cytomegalovirus directly induces the antiviral protein viperin to enhance infectivity. *Science (80-)* **332**, 1093–1097.

17 Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL & Hartmann R (2007) Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. *J Virol* **81**, 7749–7758.

18 Xiang C, Huang M, Xiong T, Rong F, Li L, Liu DX & Chen RA (2020) Transcriptomic analysis and functional characterization reveal the duck interferon regulatory factor 1 as an important restriction factor in the replication of Tembusu virus. *Front Microbiol* **11**, 2069.

19 Ghosh S & Marsh ENG (2020) Viperin: an ancient radical-SAM enzyme finds its place in modern cellular metabolism and innate immunity. *J Biol Chem.* https://doi.org/10.1074/jbc.REV120.012784.

20 Mattijssen S & Pruijn GJM (2012) Viperin, a key player in the antiviral response. *Microbes Infect* **14**, 419–426.

21 Honarmand Ebrahimi K (2018) A unifying view of the broad-spectrum antiviral activity of RSAD2 (viperin) based on its radical-SAM chemistry. *Metallomics* **10**, 539–552.

22 Gizzi AS, Grove TL, Arnold JJ, Jose J, Jangra RK, Garforth SJ, Du Q, Cahill SM, Dulyaninova NG, Love JD et al, (2018) A naturally occurring antiviral ribonucleotide encoded by the human genome. *Nature* **558**, 610–614.

23 Fenwick MK, Su D, Dong M, Lin H & Ealick SE (2020) Structural basis of the substrate selectivity of viperin. *Biochemistry* **59**, 652–662.

24 Honarmand Ebrahimi K, Rowbotham J, McCullagh J & James WS (2020) Mechanism of diol dehydration by a promiscuous radical-SAM enzyme homologue of the antiviral enzyme viperin (RSAD2). *ChemBioChem* **11**, 1605–1612.

25 Ebrahimi KH, Vowles J, Browne C, McCullagh J & James WS (2020) ddhCTP produced by the radical-SAM activity of RSAD2 (viperin) inhibits the NAD+-dependent activity of enzymes to modulate metabolism. *FEBS Lett* **10**, 1631–1644.

26 Qi Z, Xia J, Xue X, Liu J, Liu W & Zhuzhe D (2017) Targeting viperin improves diet-induced glucose intolerance but not adipose tissue inflammation. *Oncotarget* **8**, 101418–101436.

27 Zhang B, Zhang J, Xiao ZZ & Sun L (2014) Rock bream (Oplegnathus fasciatus) viperin is a virus-responsive protein that modulates innate immunity and promotes resistance against megalocytivirus infection. *Developmental Comp Immunol* **45**, 35–42.

28 Honarmand Ebrahimi K, Howie D, Rowbotham J, McCullagh J, Armstrong F & James WS (2020) Viperin, through its radical-SAM activity, depletes cellular nucleotide pools and interferes with mitochondrial metabolism to inhibit viral replication. *FEBS Lett* **10**, 1624–1630.

29 Chakravortty D & Hensel M (2003) Inducible nitric oxide synthase and control of intracellular bacterial pathogens. *Microbes Infect* **5**, 621–627.

30 Akaike T & Maeda H (2000) *Nitric oxide and virus infection. Immunology* **101**, 300–308.

31 Forstermann U, Schmidt HHHW, Pollock JS, Sheng H, Mitchell JA, Warner TD, Nakane M & Murad F (1991) Isoforms of nitric oxide synthase characterization and purification from different cell types. *Biochem Pharmacol* **42**, 1849–1857.

32 Forstermann U, Gath I, Schwarz P, Closs EI & Kleinert H (1995) Isoforms of nitric oxide synthase: Properties, cellular distribution and expressional control. *Biochem Pharmacol* **50**, 1321–1332.

33 Rosen GM, Tsai P & Pou S (2002) Mechanism of free-radical generation by nitric oxide synthase. *Chem Rev* **102**, 1191–1200.

34 Vedia LMY, McDonald B, Reep B, Brune B, Silvio MD, Billiar TR & Lapetina EG (1992) Nitric oxide-induced S-nitrosylation of glyceraldehyde-3-phosphate dehydrogenase inhibits enzymatic activity and increases endogenous ADP-ribosylation. *J Biol Chem* **267**, 24929–24932.

35 Dimmeler S, Lottspeich F & Brune B (1992) Nitric oxide causes ADP-ribosylation and inhibition of glyceraldehyde-3-phosphate dehydrogenase. *J Biol Chem* **267**, 16771–16774.

36 Mohr S, Hallak H, de Boitte A, Lapetina EG & Brune B (1999) Nitric oxide-induced S-glutathionylation and inactivation of glyceraldehyde-3-phosphate dehydrogenase. *J Biol Chem* **274**, 9427–9430.

37 Mohr S, Stamler JS & Brune B (1994) Mechanism of covalent modification of glyceraldehyde-3-phosphate dehydrogenase at its active site thiol by nitric oxide, peroxynitrite and related nitrosating agents. *FEBS Lett* **348**, 223–227.

38 Ishii T, Sunami O, Nakajima H, Nishio H, Takeuchi T & Hata F (1999) Critical role of sulfenic acid formation of thiols in the inactivation of glyceraldehyde-3-phosphate dehydrogenase by nitric oxide. *Biochem Pharmacol* **58**, 133–143.

39 Kim H, Jacobson EL & Jacobson MK (1993) Synthesis and degradation of cyclic ADP-ribose by NAD glycohydrolases. *Science (80-)* **261**, 1330–1333.

40 Lee HC (1994) Cyclic ADP-ribose: a calcium mobilizing metabolite of NAD+. *Mol Cell Biochem* **138**, 229–235.

41 Ullrich O, Ciftci O & Hass R (2000) Proteasome activation by poly-ADP-ribose-polymerase in human myelomonocytic cells after oxidative stress. *Free Radic Biol Med* **29**, 995–1004.

42 Ullrich O, Reinheckel T, Sitte N, Hass R, Grune T & Davies KJA (1999) Poly-ADP ribose polymerase activates nuclear proteasome to degrade oxidatively damaged histones. *Proc Natl Acad Sci USA* **96**, 6223–6228.

43 Berridge MJ, Bootman MD & Roderick HL (2003) Calcium signalling: dynamics, homeostasis and remodelling. *Nat Rev Cell Biol* **4**, 517–529.

44 Krebs J, Agellon LB & Michalak M (2015) Ca2+ homeostasis and endoplasmic reticulum (ER) stress: an integrated view of calcium signaling. *Biochem Biophys Res Commun* **460**, 114–121.

45 Trebak M & Kinet JP (2019) Calcium signalling in T cells. *Nat Rev Immunol* **19**, 154–169.

46 Hosoi E, Nishizaki C, Gallgher KL, Wyre HW, Matsuo Y & Sei Y (2001) Expression of the Ryanodine receptor isoforms in immune cells. *J Immunol* **167**, 4887–4894.

47 Meszaros LG, Bak J & Chu A (1993) Cyclic ADP-ribose as an endogenous regulator of the non-skeletal type ryanodine receptor Ca2+ channel. *Nature* **364**, 76–79.

48 Sonnleitner A, Conti A, Bertocchini F, Schindler H & Sorrentino V (1998) Functional properties of the ryanodine receptor type 3 (RyR3) Ca2+ release channel. *EMBO J* **17**, 2790–2798.

49 Lee HC (2012) Cyclic ADP-ribose and Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) as messengers for calcium mobilization. *J Biol Chem* **287**, 31633–31640.

50 Magnone M, Bauer I, Poggi A, Mannino E, Sturla L, Brini M, Zocchi E, De Flora A, Nencioni A & Bruzzone S (2012) NAD+ levels control Ca2+ store replenishment and mitogen-induced increase of cytosolic Ca2+ by cyclic ADP-ribose-dependent TRPM2 channel gating in human T lymphocytes. *J Biol Chem* **287**, 21067–21081.

51 Pol A, Gross SP & Parton RG (2013) Biogenesis of the multifunctional lipid droplet: lipids, proteins, and sites. *J Cell Biol* **204**, 635–646.

52 Guo Y, Cordes KR, Farese RV & Walther TC (2009) Lipid droplets at a glance. *J Cell Sci* **122**, 749–752.

53 Satoh JI (2018) Gene expression profiles of M1 and M2 microglia characterized by comparative analysis of public datasets. *Neuroimmunology* **9**, 124–138.

54 Rossa-Ballina M, Guan XL, Schmidt A & Bumann D (2020) Classical activation of macrophages leads to lipid droplet formation without de novo fatty acid synthesis. *Front Immunol* **11**, 131.

55 Dennis EA & Norris PC (2015) Eicosanoid storm in infection and inflammation. *Nat Rev Immunol* **15**, 511–523.

56 Saka HA & Valdivia R (2012) Emerging roles for lipid droplets in immunity and host-pathogen interactions. *Annu Rev Cell Dev Biol* **28**, 411–437.

57 Jarc E & Petan T (2020) A twist of FATe: Lipid droplets and inflammatory lipid mediators. *Biochimie* **169**, 69–87.

58 Balsinde J, Barbour SE, Bianco ID & Dennis EA (1994) Arachidonic acid mobilization in P388D1 macrophages is controlled by two distinct Ca(2+)-dependent phospholipase A2 enzymes. *Proc Natl Acad Sci USA* **91**, 11060–11064.

59 Channon JY & Leslie CC (1990) A calcium-dependent mechanism for associating a soluble arachidonoyl-hydrolyzing phospholipase A2 with membrane in the macrophage cell line RAW 264.7. *J Biol Chem* **265**, 5409–5413.

60 Dvorak AM, Dvorak SP, Shulman ES, MacGlashan DW Jr, Pyne K, Harvey VS, Galli SJ & Lichtenstein LM (1983) Lipid bodies: cytoplasmic organelles important to arachidonate metabolism in macrophages and mast cells. *J Immunol* **131**, 2965–2976.

61 Weller PF, Monahan-Earley RA, Dvorak HF & Dvorak AM (1991) Cytoplasmic lipid bodies of human eosinophils. Subcellular isolation and analysis of arachidonate incorporation. *Am J Pathol* **138**, 141–148.

62 Dichlberger A, Schlager S, Kovanen PT & Schneider WJ (2016) Lipid droplets in activated mast cells – a significant source of triglyceride-derived arachidonic acid for eicosanoid production. *Eur J Pharmacol* **785**, 59–69.

63 Pacia MZ, Majzner K, Czamara K, Sternak M, Chlopicki S & Baranska M (2020) Estimation of the content of lipids composing endothelial lipid droplets based on Raman imaging. *Biochim Biophys Acta (BBA)-Molecular Cell Biol Lipids* **1865**, 158758.

64 Stiebing C, Matthaus C, Krafft C, Keller AA, Weber K, Lorkowski S & Popp J (2014) Complexity of fatty acid distribution inside human macrophages on single cell level using Raman micro-spectroscopy. *Anal Bioanal Chem* **406**, 7037–7046.

65 Weller PF (2016) Leukocyte lipid bodies-structure and function as "eicosasomes". *Trans Am Clin Climatol Asoc* **127**, 328–340.

66 Kloetzel PM (2004) The proteasome and MHC class I antigen processing. *Biochim Biophys Acta* **1695**, 217–225.

67 Sijts EJAM & Kloetzel P-M (2011) The role of the proteasome in the generation of MHC class I ligands and immune responses. *Cell Mol Life Sci* **68**, 1491–1502.

68 Grant EP, Michalek MT, Goldberg AL & Rock KL (1995) Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation. *J Immunol* **155**, 3750–3758.

69 Neefjes JJ, Momburg F & Hammerling GJ (1993) Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. *Science (80-)* **261**, 769–771.

70 Karttumen JT, Trowsdale J & Lehner PJ (1999) Antigen presentation: TAP dances with ATP. *Curr Biol* **9**, R820–R824.

71 Bougneres L, Helft J, Sangeeta T, Vargas P, Chang BHJ, Chan L, Campisi L, Lauvau G, Hugues S, Kumar P *et al*, (2009) A role for lipid bodies in the cross-presentation of phagocytosed antigens by MHC class I in dendritic cells. *Immunity* **31**, 232–244.

72 Brasaemle DL, Barber T, Wolins NE, Serrero G, Blanchette-Mackie EJ & Londos C (1997) Adipose differentiation-related protein is an ubiquitously expressed lipid storage droplet-associated protein. *J Lipid Res* **38**, 2249–2263.

73 Nakamura N & Fujimoto T (2003) Adipose differentiation-related protein has two independent domains for targeting to lipid droplets. *Biochem Biophys Res Commun* **306**, 333–338.

74 den Brok MH, Bull C, Wassink M, de Graaf AM, Wagenaars JA, Minderman M, Thakur M, Amigorena S, Rijke EO, Schrier CC & *et al*, (2016) Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation. *Nat Commun* **7**, 13324.

75 Panayiotou C, Lindqvist R, Kurhade C, Vonderstein K, Pasto J, Edlund K, Upadhyay AS & Overby AK (2018) Viperin restricts Zika virus and tick-borne encephalitis virus replication by targeting NS3 for proteasomal degradation. *J Virol* **92**, e02054–e2117.

76 Klee CB, Crouch TH & Krinks MH (1979) Calcineurin: a calcium- and calmodulin-binding protein of the nervous system. *Proc Natl Acad Sci* **76**, 6270–6273.

77 Feske S, Okamura H, Hogan PG & Rao A (2003) Ca2+/calcineurin signalling in cells of the immune system. *Biochem Biophys Res Commun* **311**, 1117–1132.

78 Jain J, McCafffrey PG, Miner Z, Kerppola TK, Lambert JN, Verdine GL, Gurran T & Rao A (1993) The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. *Nature* **365**, 352–355.

79 Jeon S, Kim SH, Shin SY & Lee YH (2018) Clozapine reduces Toll-like receptor 4/NF-κB-mediated inflammatory responses through inhibition of calcium/calmodulin-dependent Akt activation in microglia. *Prog Neuro-Psychopharmacology Biol Psychiatry* **81**, 477–487.

80 Kim YH, Moon JS, Lee KS, Park SY, Cheong J, Kang HS, Lee HY & Kim HD (2004) Ca2+/calmodulin-dependent protein phosphatase calcineurin mediates the expression of iNOS through IKK and NF-κB activity in LPS-stimulated mouse peritoneal macrophages and RAW 264.7 cells. *Biochem Biophys Res Commun* **314**, 695–703.

81 Hsuan SL, Kannan MS, Jeyaseelan S, Prakash YS, Malazdrewich C, Abrahamsen MS, Sieck GC & Maheswaran SK (1999) Pasteurella haemolyticaleukotoxin and endotoxin induced cytokine gene expression in bovine alveolar macrophages

requires NF-κB activation and calcium elevation. *Microb Pathog* **26**, 263–273.

82 Macian F (2005) NFAT proteins: key regulators of T-cell development and function. *Nat Rev Immunol* **5**, 472–484.

83 Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan AD, Stroud JC, Bates DL, Guo L, Han A, Ziegler SF *et al*, (2006) FOXP3 controls regulatory T cell function through cooperation with NFAT. *Cell* **126**, 375–387.

84 Trama J, Lu Q, Hawley RG & Ho SN (2000) The NFAT-related protein NFATL1 (TonEBP/NFAT5) is induced upon T cell activation in a calcineurin-dependent manner. *J Immunol* **165**, 4884–4894.

85 Fric J, Zelante T, Wong AYW, Mertes A, Yu HB & Ricciardi-Castagnoli P (2012) NFAT control of innate immunity. *Blood* **120**, 1380–1389.

86 Mancini M & Toker A (2009) NFAT proteins: emerging roles in cancer progression. *Nat Rev Cancer* **9**, 810–820.

87 Crabtree GR & Schreiber SL (2009) SnapShot: Ca2+-Calcineurin-NFAT Signaling. *Cell* **138**, 210–210.e1.

88 Muller MR & Rao A (2010) NFAT, immunity and cancer: a transcription factor comes of age. *Nat Rev Immunol* **10**, 645–656.

89 Elloumi HZ, Maharshak N, Rao KN, Kobayashi T, Ryu HS, Muhlbauer M, Li F, Jobin C & Plevy SE (2012) A cell permeable peptide inhibitor of NFAT inhibits macrophage cytokine expression and ameliorates experimental colitis. *PLoS One* **7**, e34172.

90 Liu FX, Wu CL, Zhu ZA, Li MQ, Mao YQ, Liu M, Wang XQ, Yu DG & Tang TT (2013) Calcineurin/NFAT pathway mediates wear particle-induced TNF-α release and osteoclastogenesis from mice bone marrow macrophages in vitro. *Acta Pharmacol Sin* **34**, 1457–1466.

91 Eom J, Yoo J, Kim JJ, Lee JB, Choi W, Park CG & Seo JY (2018) Viperin deficiency promotes polarization of macrophages and secretion of M1 and M2 cytokines. *Immune Netw* **18**, e32.

92 Ranger AM, Oukka M, Rengarajan J & Glimcher LH (1998) Inhibitory function of Two NFAT Family Members in Lymphoid Homeostasis and Th2 Development. *Immunity* **9**, 627–635.

93 Qiu L-Q, Cresswell P & Chin K-C (2009) Viperin is required for optimal Th2 responses and T-cell receptor–mediated activation of NF-kB and AP-1. *Blood* **113**, 3520–3529.

94 Reiss CS & Komatsu T (1998) Does nitric oxide play a critical role in viral infections? *J Virol* 4547–4551.

95 Bogdan C, Rollinghoff M & Diefenbach A (2000) The role of nitric oxide in innate immunity. *Immunol Rev* **173**, 17–26.

96 Bogdan C (2015) Nitric oxide synthase in innate and adaptive immunity: an update. *Trends Immunol* **36**, 161–178.

97 Bogdan C (2001) Nitric oxide and the immune response. *Nat Immunol* **2**, 907–916.

98 Colasanti M, Persichini T, Venturini G & Ascenzi P (1999) S -Nitrosylation of viral proteins: molecular bases for antiviral effect of nitric oxide. *IUBMB Life* **48**, 25–31.

99 Badorff C, Fichtlscherer B, Rhoads RE, Zeiher AM, Muelsch A, Dimmeler S & Knowlton KU (2000) Nitric oxide inhibits dystrophin proteolysis by coxsackieviral protease 2A through S-nitrosylation. *Circulation* **102**, 2276–2281.

100 Zell R, Markgraf R, Schmidtke M, Gorlach M, Stelzner A, Henke A, Sigusch HH & Gluck B (2004) Nitric oxide donors inhibit the coxsackievirus B3 proteinases 2A and 3C in vitro, virus production in cells, and signs of myocarditis in virus-infected mice. *Med Microbiol Immunol* **193**, 91–100.

101 Saura M, Zaragoza C, McMillan A, Quick RA, Hohenadl C, Lowenstein JM & Lowenstein CJ (1999) An antiviral mechanism of nitric oxide: inhibition of a viral protease. *Immunology* **10**, 21–28.

102 Persichini T, Colasanti M, Lauro GM & Ascenzi P (1998) Cysteine nitrosylation inactivates the HIV-1 protease. *Biochem Biophys Res Commun* **250**, 575–576.

103 Tkhampunya R, Padmanabhan R & Ubol S (2006) Antiviral action of nitric oxide on dengue virus type 2 replication. *J Gen Virol* **87**, 3003–3011.

104 Persichini T, Colasanti M, Fraziano M, Colizzi V, Medana C, Polticelli F, Venturini G & Ascenzi P (1999) Nitric oxide inhibits the HIV-1 reverse transcriptase activity. *Biochem Biophys Res Commun* **258**, 624–627.

105 Croen KD (1993) Evidence for antiviral effect of nitric oxide. Inhibition of herpes simplex virus type 1 replication. *J Clin Invest* **91**, 2446–2452.

106 Lin YL, Huang YL, Ma SH, Yeh CT, Chiou SY, Chen LK & Liao CL (1997) Inhibition of Japanese encephalitis virus infection by nitric oxide: antiviral effect of nitric oxide on RNA virus replication. *J Virol* **71**, 5227–5235.

107 Rimmelzwaan GF, Baars MMJW, de Lijster P, Fouchier RAM & Osterhaus ADME (1999) Inhibition of influenza virus replication by nitric oxide. *J Virol* **73**, 8880–8883.

108 Bailey JD, Diotallevi M, Nicol T, McNeill E, Shaw A, Chuaiphichai S, Hale A, Starr A, Nandi M, Stylianou E *et al*, (2019) Nitric oxide modulates metabolic remodeling in inflammatory macrophages through TCA Cycle Regulation and Itaconate Accumulation. *Cell Rep* **28**, 218–230.

109 Trevillyan JM, Chiou XG, Chen YW, Ballaron SJ, Sheet MP, Smith ML, Wiedeman PE, Warrior U, Wilkins J, Gubbins EJ *et al*, (2001) Potent inhibition of NFAT activation and T cell cytokine production by

novel low molecular weight Pyrazole compounds. *J Biol Chem* **276**, 48118–48126.

110 Seo J-Y & Cresswell P (2013) Viperin regulates cellular lipid metabolism during human cytomegalovirus infection. *PloS Pathog* **9**, e1003497.

111 Wang X, Hinson ER & Cresswell P (2007) The interferon-inducible protein viperin inhibits influenza virus release by perturbing lipid rafts. *Cell Host Microbe* **2**, 96–105.

112 Saitoh T, Satoh T, Yamamoto N, Uematsu S, Takeuchi O, Kawai T & Akira S (2011) Antiviral protein viperin promotes toll-like receptor 7- and toll-like receptor 9-mediated type I interferon production in plasmacytoid dendritic cells. *Immunity* **34**, 352–363.

113 Kornberg MD, Bhargava P, Kim PM, Putluri V, Snowman AM, Putluri N, Calabresi PA & Snyder SH (2018) Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity. *Science (80-)* **360**, 449–453.

114 Liao ST, Han C, Xu DQ, Fu XW, Wang JS & Kong LY (2019) 4-Octyl itaconate inhibits aerobic glycolysis by targeting GAPDH to exert anti-inflammatory effects. *Nat Commun* **10**, 5091.

115 Blewell MM, Xie J, Zaro BW, Backus KM, Altman A, Teijaro JR & Cravatt BF (2016) Chemical proteomic map of dimethyl fumarate–sensitive cysteines in primary human T cells. *Sci Signal* **9**, rs10.